GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IN8bio Inc (NAS:INAB) » Definitions » EPS without NRI

INAB (IN8bio) EPS without NRI : $-0.56 (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is IN8bio EPS without NRI?

IN8bio's earnings per share without non-recurring items for the three months ended in Dec. 2024 was $-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.56.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 27.90% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was -3.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for IN8bio's EPS without NRI or its related term are showing as below:

INAB' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -53.6   Med: -26.55   Max: 27.9
Current: 27.9

During the past 7 years, IN8bio's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 27.90% per year. The lowest was -53.60% per year. And the median was -26.55% per year.

INAB's 3-Year EPS without NRI Growth Rate is ranked better than
70.46% of 1229 companies
in the Biotechnology industry
Industry Median: 10.3 vs INAB: 27.90

IN8bio's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.58.

IN8bio's EPS (Basic) for the three months ended in Dec. 2024 was $-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.58.


IN8bio EPS without NRI Historical Data

The historical data trend for IN8bio's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IN8bio EPS without NRI Chart

IN8bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial -0.53 -1.47 -1.36 -1.00 -0.55

IN8bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.21 -0.20 -0.19 -0.13 -0.04

Competitive Comparison of IN8bio's EPS without NRI

For the Biotechnology subindustry, IN8bio's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IN8bio's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IN8bio's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where IN8bio's PE Ratio without NRI falls into.


;
;

IN8bio EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IN8bio  (NAS:INAB) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


IN8bio EPS without NRI Related Terms

Thank you for viewing the detailed overview of IN8bio's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


IN8bio Business Description

Traded in Other Exchanges
N/A
Address
350 5th Avenue, Suite 5330, New York, NY, USA, 10118
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Executives
Jeremy R. Graff director C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Patrick Mccall officer: Chief Financial Officer C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
William Tai-wei Ho director, officer: President, CEO and CFO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Fund Ii, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Leslie W. Kreis director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp director, 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Ii Nt, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Bios Fund Ii Qp, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Fletcher Aaron G.l. director, 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Transcend Partners Opportunity Fund Llc 10 percent owner 10 ORINDA VIEW ROAD, ORINDA CA 94563
Lawrence Lamb officer: EVP and CSO C/O IN8BIO, INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Incysus Co-invest I, Lp director, 10 percent owner 1401 FOCH STREET, SUITE 140, FORT WORTH TX 76107
Trishna Goswami officer: Chief Medical Officer C/O IN8BIO, INC., 350 5TH AVENUE, SUITE 5330, NEW YORK NY 10118
Kate Rochlin officer: Chief Operating Officer IN8BIO, INC., EMPIRE STATE BUILDING, SUITE 5330, NEW YORK NY 10118